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SUMMARY – Th e aim of the study was to assess the role of the estradiol and progesterone rela-
tionship during the late luteal phase and the occurrence of fi brocystic breast disease (FBD). Th e con-
centration of estradiol/progesterone was measured in the group of women with FBD as study group 
(n=50) and control group of women without FBD (n=40). All women had regular ovulation cycles. 
Blood samples for estradiol (E2), progesterone (P) and prolactin determination were obtained in the 
morning at 8 am on days 21 and 24 of menstrual cycle. Signifi cant mastalgia and mastodynia history 
in women with FBD was obtained with yes or no questionnaire. FBD diagnosis was confi rmed with 
ultrasound (size and number of simple cysts). In the control group, a reduced E2/P ratio was noticed 
from day 21 to day 24 of the cycle (from 14.8±11.5 pg/mL to 9.1±6.1 pg/mL; p<0.05), which was 
not  recorded in the group of women with FBD (study group). Even the slightest disturbance of the 
E2/P ratio may contribute to the occurrence of FBD with clinical manifestations of mastalgia and 
mastodynia.
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Introduction
Fibrocystic breast disease (FBD), recently called 
fi brocystic changes in the literature, is the most fre-
quent benign breast disease, which is diagnosed in 
50% of the clinically and 90% of the histopathologi-
cally examined women1. Its highest incidence is be-
tween 20 and 50 years of age, when a woman is most 
exposed to stress periods, e.g., her development in the 
society, forming a family and giving birth. In this pe-
riod, her body is exposed to quite signifi cant hormone 
turbulences2-4.
Th e question is what causes the high incidence of 
these changes and how to ease the discomfort. Th e 
treatment is still just empirical, which leads the scien-
tists to search for the pathophysiological cause of the 
changes and estimate the malignant potential. It is 
noted that, even in women with healthy hygienic-diet 
regimen and no risk habits such as excessive consump-
tion of coff ee, opiates and smoking, the disease is still 
manifested.
Many researchers believe that changes in hormone 
status of prolactin, thyroid hormones and steroid ovary 
hormones may lead to development of benign changes 
in the breasts4. Although some studies show how the 
prevalence of increased estrogen concentration during 
the menstrual cycle (MC) could be one of the main 
pathophysiological disorders5, there are controversies 
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found in the literature. Th ese controversies emphasize 
the absence of negative correlation between steroid 
ovary hormones and the occurrence of benign diseases 
of the breasts6,7.
So far, very few studies monitored the relation of 
sexual ovary hormones in the late luteal phase, most 
often in the fi rst 7 days after ovulation.
Regarding the incidence, suff ering and fear caused 
by benign changes in the breasts, studying secretion of 
just these hormones in the late MC secretion phase 
seemed to be quite important. Th e study was aimed at 
assessing the correlation between the hormones and 
the disease, in order to alleviate discomfort with ap-
propriate therapy and improve emotional stability of 
the woman.
Patients and Methods
Th e study was conducted at the Department of 
Endocrinology, Clinical Center Serbia, and included 
90 women with regular MC, aged 20 to 40 years, with 
normal body mass index (BMI) and waist/hip (W/H) 
ratio. Experimental group included 50 women with 
respective history data and clinical fi ndings, existence 
of mastalgia and mastodynia, and premenstrual syn-
drome (PMS). Ultrasound (US) examination showed 
simple cysts sized <1 cm in both breasts. Control group 
consisted of 40 healthy women without discomforts 
and PMS, and with regular clinical and US fi ndings of 
the breasts.
At the beginning of the MC follicular phase, all 
women underwent hormone status testing on empty 
stomach for thyroid hormones, gonadotropic hor-
mones, prolactin (PRL), ovarian steroid hormones and 
adrenal gland, insulin and biochemical analyses (glu-
cose, urea, creatinine, cholesterol, triglycerides, liver 
transaminases, plasma iontophoresis). During the MC 
luteal phase, on days 21 and 24, blood samples were 
obtained from both groups of subjects for estrogen 
(E2), progesterone (P) and prolactin (PRL) determi-
nation. Hormone analysis was performed on a Roche 
immunoassay analyzer (modular analytics E170) by 
electrochemiluminescence using the immunoassay 
method (ECLIA). Th e Elecsys 2010 immunoassay, 
reagent kit 03000079122 was used for estrogen, Elec-
sys 2010 immunoassay, reagent kit 12145383122 for 
progesterone and Elecsys 2010 immunoassay, reagent 
kit 0320309319 for prolactin measurement.
Linear multifunction large resolution linear probe 
4.2-12 MHz, 38 mm, on a Loqic 5 GE device was 
employed for breast US examination. Th e study ex-
cluded pregnant women and those with any kind of 
malignant disease, endocrinopathy, complex dysplastic 
cysts, fi broadenoma, as well as those who were using or 
had used birth control therapy.
History data were obtained by use of question-
naires with yes/no answers on MC regularity, PMS, 
giving birth and number of births, existence of dis-
comfort in the breasts in the previous six months (ten-
sion, pain, discharge, nodularity), use of birth control 
therapy, FBD in the family, consumption of coff ee and 
cigarettes, as well as healthy hygienic-diet regimen.
Th e study was conducted according to ethical prin-
ciples and was approved by the Ethics Committee of 
the School of Medicine, University of Belgrade (no. 
29/XI-8, 2012).
Results
Estrogen concentration measured on day 21 was 
not statistically diff erent between the two groups 
(p=0.7999). Within the control group, there was a sta-
tistically signifi cant drop of E2 from day 21 to day 24 
(from 157.58±79.39 pg/mL to 124.89±52.34 pg/mL; 
p=0.010) (Fig. 1).
Progesterone concentration on day 21 of the cycle 
was not statistically signifi cantly diff erent between the 
two groups of women (p=0.116), which confi rmed the 
Fig. 1. Estradiol concentration on day 21 and 24 
of the luteal phase.
E2 = estradiol; FBD = fi brocystic breast disease; MC = menstr ual 
cycle
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ovulatory cycle. Progesterone concentration within the 
control group was higher on day 24 relative to day 
21 (from 13.79±8.66 ng/mL to 10.36±6.92 ng/mL; 
p<0.001) (Fig. 2).
In control group, the E2/P ratio on day 24 was 
9.1±6.1, which was a signifi cant decrease from day 21, 
when it was 14.8±11.1, whereas in the group of FBD 
women it increased signifi cantly from day 21 to day 24 
of the cycle (from 12.1±10.7:18.9±23.8) (Fig. 3).
In FBD women, the level of estrogen and proges-
terone defi ciency in plasma on day 24 of MC caused a 
statistically signifi cant incidence of tension and pain 
(p<0.05) (Fig. 4).
Tension and pain in the breasts were recorded in 
two women from the control group, however, it was of 
no statistical signifi cance.
Discussion
Fibrocystic breast disease is the most common 
breast disease in gynecologic and radio-oncologic 
practice. Th e most often manifested discomforts are 
pain and tension in the breasts and tender nodes pal-
pable in the breasts. Th e discomfort causes fear in 
women and interferes with their daily activities. Th e 
increasing incidence of this disease may be infl uenced 
by age, obesity, smoking, hormone preparations, PMS, 
stress, ductectasia, and alcohol and caff eine consump-
tion8.
However, in the absence of the abovementioned 
potential risk factors, the question is what other risk 
factors may infl uence the pathophysiological process 
of this disease, and whether imbalance of female sexu-
al hormones, responsible for development of female 
breasts, can lead to manifestation of this disease.
Some researchers state that disturbance of estrogen 
and progesterone plays an important role in this prob-
lem development9,10. Hormonal imbalance may be the 
consequence of changes in the concentration of steroid 
receptors and their affi  nity for estradiol and progester-
one11. Under the infl uence of estrogen, interlobular 
connective tissue collects mucosal edema, which then 
leads to its swelling and hyalinization. All this dynam-
ics could infl uence the manifestation of mastopathy 
Fig. 2. Progesterone concentration on day 21 and 24 
of the luteal phase.
P = progesterone; FBD = fi brocystic breast disease; MC = men-
strual cycle
Fig. 3. E2/P ratio in late luteal phase.
E2/P ratio = estradiol/progesterone ratio; MC = menstrual cycle; 
FBD = fi brocystic breast disease
Fig. 4. Pain and tension during luteal phase in women 
with fi brocystic breast disease.
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and sclero-cystic changes. Estrogen at the breast cell 
level enhances the synthesis of DNA, mitotic activity, 
diff erentiation and proliferation of breast cells and 
connective tissue12,13.
What happens with the breast epithelium during 
the MC secretion phase when a gradual decrease in 
the estrogen concentration is naturally expected, with 
a signifi cant rise and maintenance of the progesterone 
concentration? Th e question is why this sequence is 
missing even when the lack of progesterone is record-
ed. While estrogen gives the main impulse to the 
mammary gland proliferation, the progesterone eff ect 
is the subject of discussion. Progesterone has a positive, 
modest or no infl uence, or may even inhibit cell 
growth. Th e researchers have found that cell prolifera-
tion directly depends on the estrogen-progesterone 
ratio in the breast tissue and that it is lower in the lu-
teal than in the follicular phase14. In the breast tissue 
obtained by aspirate biopsy, it was found that a normal 
increase of progesterone in the luteal phase resulted in 
a decrease of the estrogen receptor but not progester-
one receptor regulation15. Within the normal epithe-
lial cell culture of human breast, researchers have no-
ticed the inhibitory eff ect on cell proliferation due to 
long-lasting progesterone treatment (7 days) in the 
presence or absence of estrogen. Also, the cells showed 
proliferation growth after E2 treatment and returned 
to the inactive state when P was added16.
Th e women with high estrogen relative to proges-
terone (low E2/P ratio) face a higher possibility of de-
veloping an atypical benign breast disease with an in-
creased risk of breast cancer7. Low endogenous level of 
luteal progesterone in peri-menopausal women corre-
lates with an increased risk of breast cancer17.
High level of androgen, either from ovaries or su-
prarenal glands, showed antagonistic eff ect on proges-
terone, which infl uenced FBD development, and re-
ceptor gene polymorphism, which might result in be-
nign mastopathy and breast cancer18. Recent reports 
show that higher concentrations of medroxyprogester-
one acetate (MPA) resulted in the inhibition of prolif-
eration under the infl uence of estrogen.
Rohan et al. tested the eff ect of conjugated equine 
estrogen (CEE) 0.625 mg/day as a risk for the occur-
rence of benign proliferative breast disease (BPBD) in 
the Women’s Health Initiative (WHI), a randomized 
controlled study that included 10,739 women. Th ere 
were a total of 232 newly diagnosed women with 
BPBD established during the study (the women were 
monitored for a mean of 6.9 years). Th e CEE use was 
connected with a twice higher risk of BPBD (HR-2, 
11, 95% CI=1.58-2.81)19. Th is led to a conclusion that 
there was a very important correlation between hyper-
estrogenemia and etiology of BPBD and that long-
term breast exposure to higher estradiol concentration 
(7 years and more) should be the cause of BPBD de-
velopment.
Guided by these considerations about E2 level as 
one of the BPBD causes and knowing that women in 
reproductive age have the highest estradiol concentra-
tion in plasma, we tested our patients exactly during 
this period of life.
Daily monitoring of E2/P changes during the lu-
teal phase was needed for understanding the FBD 
pathophysiology. A single sample of E2/P on day 21 
was not suffi  cient for monitoring its infl uence on the 
occurrence of cystic breast changes.
Our results showed that in FBD patients, there was 
a signifi cant decrease in progesterone concentration in 
plasma on day 24 of MC and increase in estrogen con-
centration. We postulate that it is just the maintenance 
of constant hyperestrogenemia and reduced antago-
nistic anti-proliferation eff ect of the progesterone dur-
ing the entire late luteal phase of MC that lead to the 
manifestation of discomfort and clinical fi ndings in 
the breasts of women with FBD.
We found no correlation between BMI and FBD, 
which is in line with the report by Friedenreich et al.8. 
All our patients had normal BMI range. On the con-
trary, Baer et al. found positive correlation between 
BMI and percentage of BPBD development in the 
women of reproductive age. Th e women with normal 
BMI (<25 kg/m2) had by 30% less risk of BPBD20. 
Current knowledge indicates that obesity and exces-
sive body fat represent the grounds for production of 
higher estradiol and estriol (product of estradiol trans-
formation). Th is means that higher BMI could infl u-
ence (indirectly via hyperestrogenemia) the develop-
ment of FBD.
To assess the role of prolactin in the pathogenesis 
of benign breast diseases, Sitruk-Ware et al. measured 
serum prolactin level before and during the thyrotro-
pin releasing hormone (TRH) test in patients during 
the luteal phase. Th ey measured serum level of E and P 
before and during 3 months of treatment with syn-
thetic progesterone, lynestrenol. Th ere was no signifi -
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cant diff erence in the basic secretion of prolactin be-
fore and during therapy, or after TRH injection be-
tween patients on therapy and control group21. In their 
study, Walsh et al. found increased prolactin and estra-
diol concentration in the second half of the luteal 
phase in women with benign breast disease in com-
parison with control group22. Correlation between 
prolactin level and FBD could not be found in our 
study, since all patients had normal prolactin levels.
During the lifespan, every woman sometimes feels 
cyclic pain, being most expressed in the second phase 
of MC and related to the increased intake of sweets, 
coff ee and cigarettes with changes in hormone con-
centrations23. Ayers and Gidwani monitored hormonal 
changes in the group of women with mastodynia and 
recorded a signifi cantly lower progesterone in the lu-
teal phase and increased prolactin sensitive to thyro-
tropin releasing hormone in control group24.
However, there are other opinions. Th us, in the 
study that monitored mastalgia in patients 4 to 8 days 
after ovulation, there was no correlation of dynamic 
changes with E2/P ratio, hyperprolactinemia and 
PMS in women with FBD25.
We consider that it is important to test progester-
one concentration in the fi rst or second week after 
ovulation. Th e low progesterone concentration in the 
late luteal phase was the cause of mastodynia, mastal-
gia and PMS in our subjects with FBD.
Conclusion
Normal function of breast cells and tissue depends 
on an adequate share of estradiol and progesterone 
concentration. Even the slightest disturbance of the 
E2/P ratio may contribute to the occurrence of FBD 
with clinical manifestations of mastalgia and masto-
dynia, and its correction may improve the quality of 
life, reduce the frequency of surgical treatments and 
eventually, the potential risk of developing breast car-
cinoma.
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Sažetak
ULOGA OMJERA E2/P U ETIOLOGIJI FIROCISTIČNE BOLESTI DOJKE, 
MASTALGIJE I MASTODINIJE
M. Brkić, S. Vujović, M. Ivović, M. Tančić Gajić, Lj. Marina, M. Franić Ivanišević i D. Franić
Namjera rada je bila ispitati ulogu odnosa estradiola i progesterona za vrijeme lutealne faze ciklusa u pojavljivanju fi bro-
cistične bolesti dojke (FBD). Koncentracija odnosa estradiol/progesteron je bila mjerena u skupini žena s FBD (n=50) (stu-
dijska skupina) i u kontrolnoj skupini žena bez FBD (n=40) (kontrolna skupina). Sve su žene imale redovite ovulacijske 
 cikluse. Krvni uzorci estradiola (E2), progesterona (P) i prolaktina određivali su se u 8 h ujutro 21. i 24. dana menstruacijskog 
cikusa. Određivanje značajnosti mastalgije i mastodinije bila je ispitana upitnikom da/ne. Dijagnoza FBD je bila potvr đena 
ultrazvukom dojke (veličina i broj jednostavnih cista). U kontrolnoj skupini smanjen odnos E2/P zabilježen je od 21. do 24. 
dana ciklusa (od 14,8±11,5 pg/mL do 9,1±6,1 pg/mL; p<0,05), za razliku od žena studijske skupine gdje ta promjena nije 
bila zapažena. Čak i mala promjena odnosa E2/P može doprinijeti nastanku FBD s kliničkim manifestacijama mastalgije i 
mastodinije.
Ključne riječi: Estradiol; Progesteron; Fibrocistična bolest dojke; Luteinska faza
